<DOC>
	<DOCNO>NCT01817985</DOCNO>
	<brief_summary>This Phase 1 Open-Label , Parallel-Group , Single-Dose Study evaluate Pharmacokinetics GS-5816 subject normal hepatic function moderate severe hepatic impairment .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Pharmacokinetics GS-5816 Subjects With Normal Hepatic Function Moderate Severe Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Diagnosis chronic ( &gt; 6 month ) , hepatic impairment . In opinion Investigator , good health . Severe hepatic encephalopathy . Prior placement portosystemic shunt . Hepatorenal hepatopulmonary syndrome . Suspicion hepatocellular carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Hepatitis C ( HCV ) Infection</keyword>
	<keyword>Moderate Hepatic Impairment</keyword>
	<keyword>Severe Hepatic Impairment</keyword>
</DOC>